Capecitabine Induced Multifocal Leukoencephalopathy: Do We Have Always to Switch off the Chemotherapy?
Joint Authors
Voskou, Panagiota
Kilidireas, Constantinos
Andreadou, Elisabeth
Bougea, A.
Source
Case Reports in Oncological Medicine
Issue
Vol. 2016, Issue 2016 (31 Dec. 2016), pp.1-3, 3 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2016-02-07
Country of Publication
Egypt
No. of Pages
3
Main Subjects
Abstract EN
Capecitabine is a well tolerated and safe 5-fluorouracil agent for adjuvant, neoadjuvant chemotherapy or metastatic cases.
Neurological side effects require discontinuation of chemotherapy.
We report this unique case of a 50-year-old female, who presented an isolated episode of dysarthria and ataxia under bevacizumab, capecitabine, and oxaliplatin treatment due to reversible multifocal leukoencephalopathy that did not recur after readministration of chemotherapy.
American Psychological Association (APA)
Bougea, A.& Voskou, Panagiota& Kilidireas, Constantinos& Andreadou, Elisabeth. 2016. Capecitabine Induced Multifocal Leukoencephalopathy: Do We Have Always to Switch off the Chemotherapy?. Case Reports in Oncological Medicine،Vol. 2016, no. 2016, pp.1-3.
https://search.emarefa.net/detail/BIM-1101655
Modern Language Association (MLA)
Bougea, A.…[et al.]. Capecitabine Induced Multifocal Leukoencephalopathy: Do We Have Always to Switch off the Chemotherapy?. Case Reports in Oncological Medicine No. 2016 (2016), pp.1-3.
https://search.emarefa.net/detail/BIM-1101655
American Medical Association (AMA)
Bougea, A.& Voskou, Panagiota& Kilidireas, Constantinos& Andreadou, Elisabeth. Capecitabine Induced Multifocal Leukoencephalopathy: Do We Have Always to Switch off the Chemotherapy?. Case Reports in Oncological Medicine. 2016. Vol. 2016, no. 2016, pp.1-3.
https://search.emarefa.net/detail/BIM-1101655
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1101655
